Chronic active hepatitis in the type I polyglandular autoimmune syndrome

Theresa M. Michele, Jacqueline Fleckenstein, Anita R. Sgrignoli and Paul J. Thuluvath

Division of Gastroenterology & Pathology, The Johns Hopkins University Hospital, Baltimore, MD 21205, USA

Summary: Type I polyglandular autoimmune syndrome is characterized by the triad of hypoparathyroidism, Addison's disease and chronic mucocutaneous candidiasis. Chronic active hepatitis has been associated with this syndrome but its incidence and severity have not been well documented.

We describe a sibship of two patients with type I polyglandular autoimmune syndrome who presented with autoimmune chronic active hepatitis. The first patient presented to us with advanced disease and died despite an emergent liver transplant, while the second patient responded to steroids.

Autoimmune chronic active hepatitis, a major cause of mortality in this syndrome, can present without symptoms or physical signs of liver disease. We suggest periodic screening of liver enzymes in subjects with this syndrome.

Introduction

Type I autoimmune polyglandular syndrome, also known as autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy (APECED), is a rare disorder defined by hypoparathyroidism, Addison's disease and chronic mucocutaneous candidiasis. The syndrome was first recognized by Whittaker in 1956. Other associated features include pernicious anaemia, diabetes mellitus, gonadal failure, autoimmune thyroid disease, vitiligo, alopecia, malabsorption, hypoplasia of the dental enamel and nails, keratopathy and chronic active hepatitis. The syndrome usually occurs in childhood with the peak age of onset around 12 years. Studies suggest an autosomal recessive inheritance without HLA predisposition. Although liver disease has been reported in association with this syndrome, it is poorly described in the literature. We report a sibship of two patients with this syndrome, both of whom developed autoimmune hepatitis.

Case reports

Case 1

A 10 year old girl was transferred to our institution for evaluation of jaundice. She was the product of a non-consanguineous marriage without family history of autoimmune disorders of any type except in her brother presented below. She was known to have type I polyglandular autoimmune syndrome since she was 3 years old. At the time of presentation she had hypoparathyroidism, Addison's disease and candidiasis involving nails and oral mucosa. The symptoms of liver disease started when she was 6 years old with lethargy, anorexia and jaundice that resolved spontaneously. She had multiple episodes of these symptoms during the next 4 years. At the time of admission to this hospital, her liver function tests showed aspartate aminotransferase (AST) 720 IU/l (normal 0–35 IU/l), alanine aminotransferase (ALT) 490 IU/l (normal 0–30 IU/l), alkaline phosphatase 300 IU/l (normal 30–120 IU/l), total bilirubin 600 µmol/l, direct bilirubin 440 µmol/l, albumin 36 g/l and total protein 62 g/l.

Physical examination showed icterus, oral and nail candidiasis. There was no asterixis, hepatosplenomegaly or ascites. Hepatitis A IgM and hepatitis B s antigen and hepatitis B core IgM antibody, Coombs test and anti-nuclear antibody (ANF) were negative. Serum immunoglobulins (Ig) showed marginal increase in IgG (IgG 16.5 g/l, IgA 2.7 g/l, IgM 2.3 g/l). Serum ceruloplasmin and alpha-1-anti-trypsin were normal. Slit-lamp examination did not show Kayser–Fleischer (KF) rings. Ultrasound examination of the liver was unremarkable. Liver histology showed a severe, somewhat patchy hepatitis with extensive areas of panlobular necrosis. The areas of panlobular necrosis showed a mild lobular inflammation. The histology confirmed autoimmune chronic active hepatitis and the patient was started on immunosuppression with prednisone and azathioprine. Serum tests repeated 4 weeks after starting therapy showed remarkable improvement with AST 260 IU/l, ALT 215 IU/l, total bilirubin 162 µmol/l, direct bilirubin 24 µmol/l, albumin 38 g/l and total protein 67 g/l. The patient underwent an emergent living donor liver transplantation and is doing well 1 year post transplant.

Case 2

A 21 year old male presented with a 1 year history of jaundice and a 6 month history of progressive jaundice. He was born in India and had no family history of autoimmune disorders. This patient was the only child of a non-consanguineous marriage. The patient's parents are first cousins. He presented with jaundice at the age of 1 year and has had intermittent episodes of fever of unknown origin with jaundice. At the time of referral to our institution, the patient had a serum bilirubin of 6.5 mg/dl, direct bilirubin 2.2 mg/dl, ALT 30 IU/l and AST 40 IU/l. Physical examination showed icterus, although no other symptoms of autoimmune disorders were noted. The patient was started on prednisone and azathioprine and is scheduled for liver transplantation.
rosis showed considerable bile duct proliferation indicating a duration of at least several weeks. The histological changes were consistent with a severe chronic active hepatitis. There was an inflammatory infiltrate of lymphocytes and plasma cells, and areas of panlobular necrosis with considerable bile duct proliferation. She was started on prednisone 60 mg daily on presentation, but she became encephalopathic and deteriorated rapidly over the next few days. She died despite an emergency liver transplant. The explant showed postnecrotic cirrhosis with little evidence of ongoing hepatitis (Figure 1).

**Case 2**

Six years after the death of the first patient, her 21 year old only sibling was admitted to our hospital for the management of symptomatic hypocalcaemia. He was diagnosed with type I polyglandular autoimmune syndrome when he presented at the age of seven with Addison’s disease and hypoparathyroidism. He developed diabetes mellitus when he was 13 years old and candida oesophagitis 7 years later. He also suffered from intermittent diarrhea and malabsorption.

Physical examination showed short stature, vitiligo, and positive Chovstek’s and Trousseau’s signs. Abdominal examination was unremarkable. Routine investigations revealed deranged liver biochemistry with AST 720 IU/l, ALT 1,148 IU/l, alkaline phosphatase 363 IU/l, total bilirubin 24 μmol/l, direct bilirubin 10 μmol/11, albumin 37 g/l and total protein 68 g/l. Prothrombin time was 13.1 seconds (control 10.8–12.8 seconds). He had no risk factors for viral hepatitis, was not on any hepatotoxic drugs and did not consume excess alcohol. Serology for hepatitis A IgM antibody, hepatitis B s antigen, hepatitis B core IgM and hepatitis C antibody were negative. Serum ceruloplasmin, alpha-1-anti-trypsin and ferritin were normal. Anti-liver-kidney microsomal (anti-LKM) antibody and anti-nuclear antibody (ANF) were negative; anti-mitochondrial antibody (AMA) and anti-smooth muscle antibody (ASMA) were weakly positive at 1:40 and 1:20, respectively. Immunoglobulins were raised (IgG 17 g/l, IgA 2.2 g/l and IgM 3.6 g/l). Liver biopsy showed severe hepatitis with focal bridging and panlobular necrosis (Figure 2).

Although the histological findings were aetiologically non-specific, there was a prominent plasma cell component to the inflammatory infiltrate, suggestive of an autoimmune aetiology, and there was no clinical evidence for a viral- or drug-induced hepatitis. He was started on prednisolone 40 mg daily. AST and ALT dropped to 40 IU/l and 100 IU/l, respectively, within 2 weeks of therapy and returned to normal within 6 weeks. Prior to the steroid treatment the enzymes were slowly going up and the improvement was seen within 72 hours after initiating the treatment. A liver biopsy performed 3 months after treatment showed only mild chronic portal inflammation with mild expansion of some portal areas consistent with a minimally active hepatitis. There was significant histological improvement compared to his previous biopsy; this dramatic response to steroids lends further support for an autoimmune aetiology for the patient’s hepatitis.11 He has remained well on azathioprine 50 mg daily and prednisolone 12.5 mg daily. The serology for HBV and HCV have remained negative and his liver function tests have remained normal.

**Discussion**

The patients described here had the complete triad of candidiasis, hypoparathyroidism and adrenal

---

![Figure 1](image1.png)  **Figure 1** Case 1: liver explant approximately 2 months later showing cirrhosis. Remaining viable nodule with surrounding fibrosis and bile ductule proliferation, × 50.

![Figure 2](image2.png)  **Figure 2** Case 2: Initial liver biopsy showing changes consistent with autoimmune hepatitis. Severe hepatitis with focal bridging and panlobular necrosis, × 160.
insufficiency. Case 1 had symptomatic episodes of liver disease for 4 years before she developed fulminant hepatitis. Case 2, on the contrary, was asymptomatic when he was found to have abnormal liver function tests. Both cases did not have all the characteristics of autoimmune liver disease. The immunoglobulins were only marginally raised in both cases and autoantibodies were negative. In the first case hepatitis C was not excluded since the tests were unavailable at the time of her presentation. It is also possible that these patients may have had some form of viral hepatitis (? non-A, non-B, non-C hepatitis). A common infectious organism is unlikely since there was a gap of 6 years between the presentation of case 1 and 2. The absence of risk factors for viral hepatitis and the rapid response to steroid also make viral hepatitis less likely. In case 1, who required liver transplant, the inflammatory changes had settled down quite dramatically following 2 weeks of prednisone and in case 2, the liver enzymes were rapidly increasing when prednisolone was started and the response was rapid and consistent. The liver biopsies of these patients had a significant number of plasma cells in the inflammatory component, although their serum immunoglobulins were not very high. Moreover, hypergammaglobulinemia need not always be present in autoimmune chronic active hepatitis, especially in children. On the basis of this evidence and due to its association with other autoimmune diseases, we believe that these two cases had autoimmune chronic active hepatitis.

Chronic liver disease has been reported before in association with type I polyglandular autoimmune syndrome, but not with type II or type III polyglandular syndrome. The initial observations of liver disease and its association with the type 1 syndrome were based on autopsy findings and isolated case reports. Cirrhosis and periportal fibrosis were incidental findings in many of these early reports. Before this syndrome was recognized as an autoimmune disease, and when markers for viral hepatitis were not available, it was suggested that this syndrome may be a sequel to 'hepatitis' despite the absence of clinical evidence of viral hepatitis. In a more recent study, Arulanantham et al. described a child who developed jaundice and ascites. This patient had high titres of smooth muscle antibody and high IgG levels. Liver biopsy showed plasma cell disruption of the limiting plate, rosette formation and areas of post-necrotic cirrhosis. The liver function of this patient improved with steroids and azathioprine, but the patient died as a result of viral pneumonia.

In a retrospective series of 41 patients reported by Neufeld and Blizzard, six had chronic active hepatitis. The authors did not provide detailed information about the liver disease, but they suggested that 'it is life threatening and is the most difficult organ-specific autoimmune disease to treat'. In a more recent review, Ahonen et al. reported follow-up data on 68 patients from Finland. Twelve patients had chronic hepatitis, in one of whom hepatitis was the initial presentation of the polyglandular autoimmune syndrome. Of the nine patients who died during the follow-up, two died due to fulminant hepatic failure; both had normal plasma aminotransferases prior to the onset of fatal hepatitis.

Lack of detailed information on the patients who had liver disease, from the published literature, make it difficult to draw any conclusions, but it appears that like the patients we have described, in this syndrome, the disease may be often subclinical and may have a fatal outcome if not treated early. It also appears that these patients do not exhibit all the characteristic features of autoimmune chronic active hepatitis. This observation emphasizes the importance of periodic screening of liver enzymes in subjects who are known to have this syndrome, especially as they may have no symptoms or physical signs of liver disease. Early diagnosis and intervention may prevent death due to liver failure in this rare syndrome.

In type I polyglandular syndrome, the more common disease components tend to present earlier on, with candidiasis and hypoparathyroidism being the usual presenting feature, closely followed by Addison's disease. Thus, it is unlikely that a polyendocrinopathy would be later detected in a subject who initially presents with autoimmune hepatitis, particularly if the subject is older than 20 years of age. In polyglandular autoimmunity, in general, antibody titres have not correlated well with either the presence of clinical disease or with eventual disease development.

The exact mechanism of liver damage is this syndrome remains unclear. Hitherto no studies have demonstrated liver specific autoantibodies in type I polyglandular syndrome, although antibodies against thyroid, retro-orbital tissues, adrenal gland, gastric parietal cells, intrinsic factor, germ cells, pancreas, pituitary and smooth muscle have been identified. It has been suggested that defective T-cell function may explain the multiple clinical manifestations of the disease.

Chronic active hepatitis is seen in 15–18% of patients with type I polyglandular autoimmune syndrome and it carries significant mortality. Periodic screening, a high index of suspicion, and early diagnosis and treatment will reduce mortality from liver disease in this syndrome.
References

Chronic active hepatitis in the type I polyglandular autoimmune syndrome.

T. M. Michele, J. Fleckenstein, A. R. Sgrignoli and P. J. Thuluvath

doi: 10.1136/pgmj.70.820.128

Updated information and services can be found at:
http://pmj.bmj.com/content/70/820/128

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/